Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: SOD1 inhibitor ATN-224|DRUG: exemestane|GENETIC: protein expression analysis|GENETIC: proteomic profiling|OTHER: laboratory biomarker analysis|OTHER: pharmacological study
Sponsor: Cancer Research UK